Cough, fever, and breathing difficulty could signal a Covid-19 infection. It could also be the flu. A Lucira Health diagnostic is now the first one authorized by the FDA to identify the culprit virus…
Continue Reading
A Moderna messenger RNA vaccine for influenza now has preliminary data from a pivotal study showing the shot prompted a strong immune response to the more common strains of the virus but fell short against less common strains.
The results reported Thursday are from one of two pivotal studies for the Moderna vaccine, mRNA-1010, which is assessing the shot for safety and immune response. A separate Phase 3 study is evaluating the shot for efficacy. Results from that study could come as early as next month. Moderna’s vaccine encodes hemagglutinin, a protein on the surface of the influenza virus that is also…
![How to Leverage Diagnostic Development to Guard Against RSV, Flu and Covid-19 [Sponsored]](https://i0.wp.com/www.mediformatica.com/wp-content/uploads/2023/02/how-to-leverage-diagnostic-development-to-guard-against-rsv-flu-and-covid-19-sponsored.jpg?fit=600%2C349&ssl=1)
For the first two years of the Covid-19 pandemic, healthcare professionals focused on understanding the Covid-19 virus, how best to guard against it, and developing tests to detect it. They also tracked, aggregated, and analyzed health data to assess and monitor the public health threat on a regional, state and country-wide level. In the longer term, vaccine development and distribution were used to slow the spread to avoid a collapse of the health system and to reduce the potency of the virus for the majority of people.
More recently, attention has shifted to the long perceived threat of viruses coming together with…
Vir Biotechnology’s Covid-19 research may yield more drugs and perhaps a vaccine, but no longer with the financial support of GSK. The collaboration agreement the two companies struck up in the early days of the pandemic has been amended, leaving Vir to either find another partner or continue its coronavirus research on its own.
The alliance did successfully develop the Covid-19 drug sotrovimab. GSK and Vir will continue to share responsibilities for that drug, which is available under the brand name Xevudy in more than 40 countries. The U.S. is no longer one of them. Last April, the FDA withdrew emergency authorization…
